I always loved science and I knew from an early age that I wanted to go into something related to biotech. But when I was younger, I also wanted to serve – and figured that was best while I was still young! My original plan was to serve for around five years and then go off to grad school to begin my second career.
After high school, I went straight into the military academy, where I majored in chemistry and life sciences. Normally, when you graduate from the military academy at West Point, you enter military service, but I was able to obtain the Hertz Foundation Fellowship, which allowed me to spend two years at graduate school. I then went back into regular military service, serving in infantry and cavalry units. While deployed in Baghdad, Iraq, I saw many serious injuries – injuries that would influence my research later down the line. After deployment, I used the remaining years of support from the Hertz Foundation Fellowship to do a PhD at MIT – so I was on active duty the whole time I was studying.
I was fortunate enough to have the flexibility within the military to pursue assignments that were technical in nature; I was able to serve in the Research and Development Command for the US Army, which allowed me to continue with military service while completing three technically connected programs within the biopharma space.
A military career and a scientific career are not a very common combination – and actually I don’t recommend it because of the difficulties of navigating the requirements for each – but it worked out for me.
I noticed that people would suffer serious injuries, mainly to limbs, which doctors would be able to save. Then, many months later, they’d have to be amputated because the limb had deeper tissues (bone, vessels or nerves) that hadn’t healed properly. It seemed strange to me that we hadn’t figured out how to target certain tissues for regenerative repair. So my aim was to develop a technology for the targeted delivery of biologics to enable tissue repair – bone regeneration in particular. And that was the basis of my research in Linda Griffith’s lab at MIT and Richard Lee at Harvard. Linda is a pioneer in tissue engineering, and I was able to learn about the techniques for modifying implants and influencing how the body regenerates. I retired from the military in 2017 to commercialize the technology with Theradaptive.
For tissue to regenerate, biological cues must be presented at the right time and place. Though we know what many of the cues are, there has been no way to deliver them to the right tissues and keep them there long enough to have a regenerative effect. In our work we developed a means of modifying proteins via a simple one-step process that doesn’t require chemical modification so that they stick – like paint – to surfaces, such as medical devices. By coating medical devices with bioactive beacons for healing, the body is triggered to surround the implant with regenerating tissue. We made a variant of a protein called bone morphogenetic protein 2. Our variant is called AMP2, and it binds to both permanent and resorbable implants and causes the body to produce bone wherever it is placed in the body. In all studies we have conducted to date we have beaten the standard of care in bone repair and spinal fusion using AMP2 – and we’ve had several meetings with the FDA. We’re hoping to begin the human phase of development within the next year and a half.
We also have promising results in cartilage repair, with another implant binding protein. The idea is that we might be able to take a “legacy” implant and regenerate the tissue it is working to support. The original idea for the technology was related to traumatic injuries sustained by soldiers, but we now see a great deal of benefit in orthopedic conditions. The projected orthopedic repair market in the US exceeds $15 billion annually, which highlights the need for targeted tissue repair in the general population. But we also believe the technology could improve cell therapy by giving cells long-lasting, local, and highly-concentrated biological stimuli. We’re still a relatively small company, hence our initial focus on trauma and the spine (funded primarily by the Department of Defense and the State of Maryland). We just closed a Series A investment round, which will allow us to expand into additional areas.
Yes, I think so. In business, you have to deal with difficult situations (and people!), for which the military certainly prepares you. I’ve gained a certain amount of resilience to overcome things that at first may seem difficult – or even impossible. For example, if the company is running low on funding or you are facing daunting challenges, persistence and resilience are great assets. The military also teaches you leadership skills – the ability to assemble a team and give them a mission to go after. But I would say that, whatever your background, starting a company is difficult and time consuming, with many unexpected twists and turns. On the other hand, it’s a lot of fun too.
I would say that moving into drug development or biotech can feel intimidating – but it’s a lot like jumping into cold water: it's always scarier before you've done it.
The technology transfer for BrainStorm's NurOwn® autologous cell therapy at Catalent’s facility has been finalized. NurOwn will be manufactured at Catalent’s world-class 32,000 square-foot cell therapy manufacturing facility in Houston.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
